[Clinical and predictive effects of α-2a-pegylated interferon in inactive HBsAg carriers]
Zhonghua Gan Zang Bing Za Zhi
.
2017 Jun 20;25(6):466-468.
doi: 10.3760/cma.j.issn.1007-3418.2017.06.015.
[Article in Chinese]
Authors
Y H Liu
1
,
L Liu
,
C Y Liu
,
W K Li
,
T Jia
,
D Peng
,
H M Li
,
L X Chang
Affiliation
1
Department of Liver Disease, the Third People's Hospital of Kunming, Kunming 650041, China.
PMID:
28763867
DOI:
10.3760/cma.j.issn.1007-3418.2017.06.015
No abstract available
Keywords:
Hepatitis B; Hepatitis B surface antigens; Pegylated interferon α-2a; Treatment outcome.